EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieVergleichsstudie

Aspirin-free strategy for percutaneous coronary intervention in acute coronary syndrome based on the subtypes of acute coronary syndrome and high bleeding risk: the STOPDAPT-3 trial

Yuki Obayashi iD, Masahiro Natsuaki, Hirotoshi Watanabe, Takeshi Morimoto iD, Ko Yamamoto, Ryusuke Nishikawa, Kenji Ando, Satoru Suwa, Tsuyoshi Isawa iD, Hiroyuki Takenaka, Tetsuya Ishikawa, Hideo Tokuyama und 10 weitere

European Heart Journal - Cardiovascular Pharmacotherapy · 14.08.2024 · 10 (5) · 374-390

DOI: 10.1093/ehjcvp/pvae009 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift European Heart Journal - Cardiovascular Pharmacotherapy, online erschienen am 29.01.2024. Verfasst von Yuki Obayashi und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan. Hauptthemen laut MEDLINE: Percutaneous Coronary Intervention, Acute Coronary Syndrome, Platelet Aggregation Inhibitors, Hemorrhage. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: Abbott Vascular.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and aims High bleeding risk (HBR) and acute coronary syndrome (ACS) subtypes are critical in determining bleeding and cardiovascular event risk after percutaneous coronary intervention (PCI). Methods and results In 4476 ACS patients enrolled in the STOPDAPT-3, where the no-aspirin and dual antiplatelet therapy (DAPT) strategies after PCI were randomly compared, the pre-specified subgroup analyses were conducted based on HBR/non-HBR and ST-segment elevation myocardial infarction (STEMI)/non-ST-segment elevation ACS (NSTE-ACS). The co-primary bleeding endpoint was Bleeding Academic Research Consortium (BARC) type 3 or 5, and the co-primary cardiovascular endpoint was a composite of cardiovascular death, myocardial infarction, definite stent thrombosis, or ischaemic stroke at 1 month. Irrespective of the subgroups, the effect of no-aspirin compared with DAPT was not significant for the bleeding endpoint (HBR [N = 1803]: 7.27 and 7.91%, hazard ratio (HR) 0.91, 95% confidence interval (CI) 0.65–1.28; non-HBR [N = 2673]: 3.40 and 3.65%, HR 0.93, 95% CI 0.62–1.39; Pinteraction = 0.94; STEMI [N = 2553]: 6.58 and 6.56%, HR 1.00, 95% CI 0.74–1.35; NSTE-ACS [N = 1923]: 2.94 and 3.64%, HR 0.80, 95% CI 0.49–1.32; Pinteraction = 0.45), and for the cardiovascular endpoint (HBR: 7.87 and 5.75%, HR 1.39, 95% CI 0.97–1.99; non-HBR: 2.56 and 2.67%, HR 0.96, 95% CI 0.60–1.53; Pinteraction = 0.22; STEMI: 6.07 and 5.46%, HR 1.11, 95% CI 0.81–1.54; NSTE-ACS: 3.03 and 1.71%, HR 1.78, 95% CI 0.97–3.27; Pinteraction = 0.18). Conclusion In patients with ACS undergoing PCI, the no-aspirin strategy compared with the DAPT strategy failed to reduce major bleeding events irrespective of HBR and ACS subtypes. The numerical excess risk of the no-aspirin strategy relative to the DAPT strategy for cardiovascular events was observed in patients with HBR and in patients with NSTE-ACS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Percutaneous Coronary InterventionAcute Coronary SyndromePlatelet Aggregation InhibitorsHemorrhageAspirinST Elevation Myocardial InfarctionDual Anti-Platelet TherapyHumansMaleFemaleAgedMiddle AgedRisk AssessmentRisk FactorsTreatment OutcomeTime FactorsNon-ST Elevated Myocardial InfarctionIschemic Stroke

Stichwörter der Autor:innen

Acute coronary syndromeAntiplatelet therapyHigh bleeding riskNon-ST-segment elevation acute coronary syndromeST-segment elevation myocardial infarction

Substanzen

Platelet Aggregation InhibitorsAspirin

Autor:innen und Institutionen

  • Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan.
  • Department of Cardiovascular Medicine, Saga University, Saga 849-8501, Japan.
  • Division of Cardiology, Hirakata Kohsai Hospital, Hirakata 573-0153, Japan.
  • Department of Clinical Epidemiology, Hyogo Medical University, Nishinomiya 663-8501, Japan.
  • Department of Cardiology, Kokura Memorial Hospital, Kitakyusyu 802-8555, Japan.
  • Department of Cardiology, Juntendo University Shizuoka Hospital, Izunokuni 410-2295, Japan.

ORCID-Profile: Yuki Obayashi, Takeshi Morimoto, Tsuyoshi Isawa, Mamoru Nanasato, Koh Ono, Takeshi Kimura

Förderung

  • Abbott Vascular

Zitieren

APA

Obayashi, Y., Natsuaki, M., Watanabe, H., Morimoto, T., Yamamoto, K., Nishikawa, R., Ando, K., Suwa, S., Isawa, T., Takenaka, H., Ishikawa, T., Tokuyama, H., Sakamoto, H., Fujita, T., Nanasato, M., Okayama, H., Nishikura, T., Kirigaya, H., Nishida, K., …, & STOPDAPT-3 investigators (2024). Aspirin-free strategy for percutaneous coronary intervention in acute coronary syndrome based on the subtypes of acute coronary syndrome and high bleeding risk: the STOPDAPT-3 trial. European Heart Journal - Cardiovascular Pharmacotherapy, 10(5), 374-390. https://doi.org/10.1093/ehjcvp/pvae009

Vancouver

Obayashi Y, Natsuaki M, Watanabe H, Morimoto T, Yamamoto K, Nishikawa R, et al. Aspirin-free strategy for percutaneous coronary intervention in acute coronary syndrome based on the subtypes of acute coronary syndrome and high bleeding risk: the STOPDAPT-3 trial. European Heart Journal - Cardiovascular Pharmacotherapy. 2024;10(5):374-390. doi:10.1093/ehjcvp/pvae009

BibTeX
@article{Obayashi2024,
  author = {Obayashi, Yuki and Natsuaki, Masahiro and Watanabe, Hirotoshi and Morimoto, Takeshi and Yamamoto, Ko and Nishikawa, Ryusuke and Ando, Kenji and Suwa, Satoru and Isawa, Tsuyoshi and Takenaka, Hiroyuki and Ishikawa, Tetsuya and Tokuyama, Hideo and Sakamoto, Hiroki and Fujita, Takanari and Nanasato, Mamoru and Okayama, Hideki and Nishikura, Tenjin and Kirigaya, Hidekuni and Nishida, Koji and Ono, Koh and Kimura, Takeshi and STOPDAPT-3 investigators, STOPDAPT-3 investigators},
  title = {Aspirin-free strategy for percutaneous coronary intervention in acute coronary syndrome based on the subtypes of acute coronary syndrome and high bleeding risk: the STOPDAPT-3 trial},
  journal = {European Heart Journal - Cardiovascular Pharmacotherapy},
  year = {2024},
  volume = {10},
  number = {5},
  pages = {374--390},
  doi = {10.1093/ehjcvp/pvae009}
}
Kostenlos starten →